RTW Investments LP Takes $45.36 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

RTW Investments LP acquired a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,850,648 shares of the company's stock, valued at approximately $45,359,000. RTW Investments LP owned 152.95% of Oruka Therapeutics at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ORKA. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics during the third quarter worth $1,037,000. Janus Henderson Group PLC bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth about $5,840,000. Redmile Group LLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at about $10,091,000. Point72 Asset Management L.P. bought a new stake in Oruka Therapeutics in the third quarter valued at about $11,822,000. Finally, Great Point Partners LLC acquired a new position in Oruka Therapeutics in the third quarter worth about $12,614,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock traded down $0.63 on Thursday, reaching $20.34. The company's stock had a trading volume of 69,423 shares, compared to its average volume of 68,499. Oruka Therapeutics, Inc. has a twelve month low of $18.20 and a twelve month high of $53.88. The stock has a market capitalization of $711.90 million, a P/E ratio of -3.25 and a beta of 0.78. The company's fifty day moving average is $25.34.

Analysts Set New Price Targets

ORKA has been the topic of a number of recent research reports. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Leerink Partnrs raised Oruka Therapeutics to a "strong-buy" rating in a research note on Tuesday, September 17th. Lifesci Capital started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set an "outperform" rating and a $41.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Monday, November 25th. Finally, Leerink Partners began coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They issued an "outperform" rating and a $44.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $43.17.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.